Summary
Results from the Clazosentan in Reducing Vasospam-Related Morbidity and Mortality in Adult Patients with Aneurysmal Subarachnoid Hemorrhage Treated By Surgical Clipping [CONSCIOUS-2; NCT00558311] study indicate that the use of the endothelin receptor antagonist clazosentan does not significantly improve vasospasm-related morbidity or all-cause mortality after aneurysmal subarachnoid hemorrhage.
- Ischemia
- Cerebrovascular Disease
- © 2011 MD Conference Express
Tools
No Significant Improvement in Vasospasm-Related Morbidity or All-Cause Mortality with Clazosentan after aSAH
Permalink:
Table of contents
Cited By...
- No citing articles found.